<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">glaucoma</journal-id><journal-title-group><journal-title xml:lang="ru">Национальный журнал Глаукома</journal-title><trans-title-group xml:lang="en"><trans-title>National Journal glaucoma</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-4104</issn><issn pub-type="epub">2311-6862</issn><publisher><publisher-name>Federal State Budgetary Institution of Science “Krasnov Research Institute of Eye Diseases”</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.25700/NJG.2018.04.03</article-id><article-id custom-type="elpub" pub-id-type="custom">glaucoma-210</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Целесообразность применения дифференцированных («ступенчатых») стартовых подходов к лечению больных с разными стадиями глаукомы</article-title><trans-title-group xml:lang="en"><trans-title>The feasibility of adopting «stepwise» initial approaches in treatment of patients with different stages of glaucoma</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куроедов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuroyedov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, начальник отделения.</p><p>107014,  Москва, ул. Большая Оленья, 8А.</p></bio><bio xml:lang="en"><p> Med.Sc.D., M.D., professor, Head of Ophthalmology Department.</p><p>8A Bolshaya Olenya st., Moscow, 107014.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Брежнев</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Brezhnev</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p> к.м.н., доцент.</p><p> 305041,  Курск, ул. Карла Маркса, 3.</p></bio><bio xml:lang="en"><p> Ph.D., M.D., assistant professor.</p><p> 3 Karl Marx st., Kursk, 305041.</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ловпаче</surname><given-names>Дж. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Lovpache</surname><given-names>J. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p> к.м.н., эксперт по вопросам глаукомы.</p><p> 129301,  Москва, ул. Бориса Галушкина, 3.</p></bio><bio xml:lang="en"><p> Ph.D., M.D., glaucoma expert.</p><p> 3 Borisa Galushkina Str., Moscow, 129301.</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петров</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrov</surname><given-names>S. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p> к.м.н., ведущий научный сотрудник.</p><p>119021, Москва, ул. Россолимо, 11А.</p></bio><bio xml:lang="en"><p> Med.Sc.D., M.D., leading researcher.</p><p>11A Rossolimo st., Moscow, 119021.</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тибиева</surname><given-names>З. У.</given-names></name><name name-style="western" xml:lang="en"><surname>Tibieva</surname><given-names>Z. U.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант, врач-офтальмолог.</p><p>117997, Москва, ул. Островитянова, 1. </p></bio><bio xml:lang="en"><p> M.D., postgraduate student.</p><p>1 Ostrovityanova st., Moscow,  117997.</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нагорнова</surname><given-names>З. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Nagornova</surname><given-names>Z. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p> аспирант, ассистент кафедры.</p><p>153012,  Иваново, Шереметьевский проспект, 8. </p></bio><bio xml:lang="en"><p>M.D., assistant professor.</p><p> 8 Sheremetevskiy av., Ivanovo,  153012.</p></bio><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Криницына</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Krinitsyna</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> клинический ординатор.</p><p>117997,  Москва, ул. Островитянова, 1.</p></bio><bio xml:lang="en"><p>resident.</p><p> 1 Ostrovityanova st., Moscow,  117997.</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сергеева</surname><given-names>В. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Sergeeva</surname><given-names>V. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p> студент.</p><p>119991, Российская Федерация, Москва, ул. Трубецкая, 8, стр. 2. </p></bio><bio xml:lang="en"><p> medical student.</p><p> 8s2 Trubetskaya st., Moscow,  119991.</p></bio><xref ref-type="aff" rid="aff-7"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФКУ «ЦВКГ им. П.В. Мандрыка» МО РФ; Кафедра офтальмологии лечебного факультета им. акад. А.П. Нестерова ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» МЗ РФ.<country>Россия</country></aff><aff xml:lang="en">Mandryka Military Clinical Hospital; Pirogov State National Medical University, Ophthalmology Department.<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБОУ ВО КГМУ МЗ РФ.<country>Россия</country></aff><aff xml:lang="en">State Medical University.<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">ООО «Три-З».<country>Россия</country></aff><aff xml:lang="en">LLC «Tri-Z-MSK».<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru">ФГБНУ «НИИГБ».<country>Россия</country></aff><aff xml:lang="en">Scientific Research Institute of Eye Diseases.<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru">Кафедра офтальмологии лечебного факультета им. акад. А.П. Нестерова ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» МЗ РФ.<country>Россия</country></aff><aff xml:lang="en">Pirogov State National Medical University, Ophthalmology Department.<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru">Кафедра оториноларингологии и офтальмологии ФГБОУ ВО «Ивановская государственная медицинская академия» МЗ РФ.<country>Россия</country></aff><aff xml:lang="en">State Medical Academy.<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-7"><aff xml:lang="ru">ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» МЗ РФ.<country>Россия</country></aff><aff xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University).<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>27</day><month>12</month><year>2018</year></pub-date><volume>17</volume><issue>4</issue><fpage>27</fpage><lpage>54</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Куроедов А.В., Брежнев А.Ю., Ловпаче Д.Н., Петров С.Ю., Тибиева З.У., Нагорнова З.М., Криницына Е.А., Сергеева В.М., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Куроедов А.В., Брежнев А.Ю., Ловпаче Д.Н., Петров С.Ю., Тибиева З.У., Нагорнова З.М., Криницына Е.А., Сергеева В.М.</copyright-holder><copyright-holder xml:lang="en">Kuroyedov A.V., Brezhnev A.Y., Lovpache J.N., Petrov S.Y., Tibieva Z.U., Nagornova Z.M., Krinitsyna E.A., Sergeeva V.M.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.glaucomajournal.ru/jour/article/view/210">https://www.glaucomajournal.ru/jour/article/view/210</self-uri><abstract><p>Классическая схема режимов назначений у больных с впервые выявленной первичной открытоугольной глаукомой (ПОУГ) подразумевает «старт» лечения па- циентов с применения монотерапии, причем это практикуется у пациента с любой стадией болезни, что подразумевает последовательное усиление режимов. Таким образом, современный клинический алгоритм практически исключает возможность «старта» лечения с использованием комбинированных форм препаратов, лазерного лечения или традиционной хирургии. Вместе с тем практикуемые в других дисциплинах дифференцированные («ступенчатые») подходы позволяют достигать контроля над заболеванием с применением наименьшего, но достаточного количества препаратов (режимов) в зависимости от стадии глаукомы, компенсации уровня внутриглазного давления (ВГД) и стабилизации глаукомного процесса в целом.</p><p>Значимые исследования в области допустимых значений офтальмотонуса, которые на фоне проводимого лечения не приводили бы к быстрым негативным морфофункциональным изменениям зрительного анализатора, по-прежнему немногочисленны. Анализ приведенных в обзоре клинико-эпидемиологических результатов исследований, установленной гипотензивной эффективности разных режимов лечения и прогнозируемых сроков нарушения толерантности к действующему веществу убедительно доказывают целесо- образность использования дифференцированных схем «стартового» лечения. В этом смысле дифференцированные («ступенчатые») подходы, включающие вы- бор монотерапии с использованием аналогов простагландинов на «старте» лечения у больных с впервые выявленной начальной стадией глаукомы, обязательное использование комбинаций (лучше — фиксированных) у пациентов с развитой стадией болезни и минимум тройная терапия с прогнозируемым переходом к быстрому хирургическому лечению у больных с далеко зашедшей стадией — это еще один рациональный вариант использования ограниченного количества ресурсов, при помощи которых мы сможем достигнуть оптимального результата.</p></abstract><trans-abstract xml:lang="en"><p>The “classical” scheme of prescribing regimens to patients with newly diagnosed primary open-angle glaucoma (POAG) implies initial monotherapy treatment, which is practiced in patients with any stage of the disease. This in turn implies a consistent strengthening of regimes.  Thus, the “modern” clinical algorithm practically excludes the possibility of initial treatment with combined medicines, laser treatment or conventional surgery. At the same time, differentiated («stepwise») approache used in other disciplines makes it possible to achieve control over the disease with the use of the smallest, but sufficient amount of medicines (regimens), depending on the stage of treatment, intraocular pressure (IOP) compensation and stabilization of the glaucomatous optic neuropathy.</p><p>Significant research in the field of permissible IOP-level values, which against the background of the ongoing treatment would not lead to rapid negative morphofunctional changes of the visual analyzer, is still few. The analysis of the clinical and epidemiological results of the studies given in the review, the established hypotensive efficacy of different treatment regimens and the predicted terms of the active substance tolerance violation convincingly prove the feasibility of using differentiated schemes of initial treatment. «Stepwise» approach, including the choice  of monotherapy with the use of a prostaglandin analogues at the «start» of treatment in patients with a newly identified mild glaucoma, mandatory use of combinations (preferably fixed) in patients with moderate stage of the disease and a minimum of triple therapy with a predicted transition to rapid surgical treatment in patients with advanced stage is another rational variant of using a limited amount of resources with which we can achieve the final result.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>первичная открытоугольная гла¬укома</kwd><kwd>клинико-эпидемиологические исследования</kwd><kwd>«стартовая» терапия</kwd><kwd>режимы лечения</kwd><kwd>«ступенчатые» подходы</kwd><kwd>аналоги простагландинов</kwd><kwd>комбинированная терапия</kwd><kwd>«тройная» терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>primary open-angle glaucoma</kwd><kwd>clinical epidemiological studies</kwd><kwd>initial therapy</kwd><kwd>treatment regimens</kwd><kwd>«stepwise» approaches</kwd><kwd>prostaglandin analogues</kwd><kwd>combine and «triple» therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Национальное руководство по глаукоме для практикующих врачей. М.: ГЭОТАР-Медиа; 2015: 456.</mixed-citation><mixed-citation xml:lang="en">Nacional’noe rukovodstvo po glaukome dlya praktikuuyschikh vrachey. [National glaucoma guideline for practitioners]. Moscow, GEOTAR-Media; 2015: 456. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Нестеров А.П. Глаукома. Москва: ООО «Мединформ агентство»; 2008:360.</mixed-citation><mixed-citation xml:lang="en">Nesterov A.P. Glaucoma. Moscow: Medical informational agency Publ.; 2008:360. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Нестеров А.П., Егоров Е.А. О патогенезе глаукоматозной атро¬фии зрительного нерва. Офтальмологический журнал. 1979; 7:419-422.</mixed-citation><mixed-citation xml:lang="en">Nesterov A.P., Egorov E.A. About the pathogenesis of glaucomatous optic nerve atrophy. Ophthalmology Journal (USSR). 1979; 7:419-422. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Фокин В.П., Балалин С.В., Борискина Л.Н. Толерантность и инто- лерантность зрительного нерва при первичной открытоугольной глаукоме. Волгоград; 2016: 208.</mixed-citation><mixed-citation xml:lang="en">Fokin V.P., Balalin S.V., Boriskina L.N. Tolerantnost’ i intolerantnost’ zritel’nogo nerva pri pervichnoy otkrytougol’noy glaukome. [Toler¬ance and intolerance of the optic nerve in primary open-angle glau¬coma]. Volgograd; 2016:208. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Водовозов А.М. Толерантное и интолерантное внутриглазное дав¬ление при глаукоме. Волгоград; 1991:160.</mixed-citation><mixed-citation xml:lang="en">Vodovozov A.M. Tolerantnoe i intolerantnoe vnutriglaznoe davlenie pri glaukome. [Tolerant and intolerant intraocular pressure in glau¬coma]. Volgograd; 1991:160 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">European Glaucoma Society Terminology and Guidelines for Glau¬coma, 4th Edition - Chapter 3: Treatment principles and options. Br JOphthalmol. 2017; 101(6):130-195.</mixed-citation><mixed-citation xml:lang="en">European Glaucoma Society Terminology and Guidelines for Glau¬coma, 4th Edition - Chapter 3: Treatment principles and options. Br J Ophthalmol. 2017; 101(6):130-195.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеев В.Н., Егоров Е.А., Мартынова Е.Б. О распределении уровней внутриглазного давления в нормальной популяции. РМЖКлиническая офтальмология. 2001; 2(2):38-40.</mixed-citation><mixed-citation xml:lang="en">Alexeev V.N., Egorov E.A., Martynova E.B. Intraocular pressure levels distribution in normal population. RMJ Clinical Ophthalmology. 2001; 2(2):38-40 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hiller R., Podgor M.J., Sperduto R.D. et al. High intraocular pres¬sure and survival: the Framingham Studies. Am J Ophthalmol. 1999; 128(4):440-445.</mixed-citation><mixed-citation xml:lang="en">Hiller R., Podgor M.J., Sperduto R.D. et al. High intraocular pres¬sure and survival: the Framingham Studies. Am J Ophthalmol. 1999; 128(4):440-445.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Куроедов А.В., Городничий В.В. Центральная толщина рогови¬цы как фактор риска прогрессирования первичной глаукомы. Глаукома. 2008; 4:20-28.</mixed-citation><mixed-citation xml:lang="en">Kuroyedov A.V., Gorodnichy V.V. Central corneal thickness as a risk factor for glaucoma progression. Glaucoma. 2008; 4:20-28. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Водовозов А.М., Борискина Л.Н. Значение индекса интолерант- ности в определении прогноза глаукомы. Офтальмологический журнал. 1985; 1:36-39.</mixed-citation><mixed-citation xml:lang="en">Vodovozov A.M., Boriskina L.N. Importance of intolerance index in glaucoma prognosis. Ophthalmology Journal (USSR). 1985; 1:36-39. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">World Glaucoma Association Consensus Statement: Intraocular Pres¬sure. The Netherlands: Kluger; 2007:226.</mixed-citation><mixed-citation xml:lang="en">World Glaucoma Association Consensus Statement: Intraocular Pres¬sure. The Netherlands: Kluger; 2007:226.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jampel H.D. Target pressure in glaucoma therapy. J Glaucoma. 1997; 6(2):133-138.</mixed-citation><mixed-citation xml:lang="en">Jampel H.D. Target pressure in glaucoma therapy. J Glaucoma. 1997; 6(2):133-138.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez A., Sanchez M. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open- angle glaucoma: a single-center, 4-year, open-label study. Clin Ther. 2008; 30(6):1120-1134.</mixed-citation><mixed-citation xml:lang="en">Martinez A., Sanchez M. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open- angle glaucoma: a single-center, 4-year, open-label study. Clin Ther. 2008; 30(6):1120-1134.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez A., Sanchez-Salorio M. A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. J Ocul Pharm Ther. 2009; 25(3):239-248.</mixed-citation><mixed-citation xml:lang="en">Martinez A., Sanchez-Salorio M. A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. J Ocul Pharm Ther. 2009; 25(3):239-248.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Krupin T., Liebmann J.M., Greenfield D.S. et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011; 151(4):671-681.</mixed-citation><mixed-citation xml:lang="en">Krupin T., Liebmann J.M., Greenfield D.S. et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011; 151(4):671-681.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Егоров Е.А., Брежнев А.Ю., Егоров А.Е. Нейропротекция при глаукоме: современные возможности и перспективы. РМЖ Клиническая офтальмология. 2014; 14(2):108-112.</mixed-citation><mixed-citation xml:lang="en">Егоров Е.А., Брежнев А.Ю., Егоров А.Е. Нейропротекция при глаукоме: современные возможности и перспективы. РМЖ Клиническая офтальмология. 2014; 14(2):108-112.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kass M.A., Heuer D.K., Higginbotham E.J. et al. The Ocular Hyper¬tension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120:701-713.</mixed-citation><mixed-citation xml:lang="en">Kass M.A., Heuer D.K., Higginbotham E.J. et al. The Ocular Hyper¬tension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120:701-713.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Miglior S., Zeyen T., Pfeiffer N. et al. European Glaucoma Prevention Study (EGPS) Group Results of the European Glaucoma Prevention Study. Ophthalmology. 2005; 112(3):366-375.</mixed-citation><mixed-citation xml:lang="en">Miglior S., Zeyen T., Pfeiffer N. et al. European Glaucoma Prevention Study (EGPS) Group Results of the European Glaucoma Prevention Study. Ophthalmology. 2005; 112(3):366-375.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Heijl A., Leske M.C., Bengtsson B. et al. Reduction of intraocular pres¬sure and glaucoma progression: results from the Early Manifest Glau¬coma Trial. Arch Ophthalmol. 2002; 120(10):1268-1279.</mixed-citation><mixed-citation xml:lang="en">Heijl A., Leske M.C., Bengtsson B. et al. Reduction of intraocular pres¬sure and glaucoma progression: results from the Early Manifest Glau¬coma Trial. Arch Ophthalmol. 2002; 120(10):1268-1279.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Leske M.C., Heijl A., Hussein M. et al. Factors for glaucoma progres¬sion and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003; 121(1):48-56.</mixed-citation><mixed-citation xml:lang="en">Leske M.C., Heijl A., Hussein M. et al. Factors for glaucoma progres¬sion and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003; 121(1):48-56.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lichter P.R., Musch D.C., Gillespie B.W. et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing ini¬tial treatment randomized to medications or surgery. Ophthalmology. 2001; 108(11):1943-1953.</mixed-citation><mixed-citation xml:lang="en">Lichter P.R., Musch D.C., Gillespie B.W. et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing ini¬tial treatment randomized to medications or surgery. Ophthalmology. 2001; 108(11):1943-1953.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Musch D.C., Gillespie B.W., Lichter P.R. et al. Visual field progres¬sion in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology. 2009; 116(2):200-207.</mixed-citation><mixed-citation xml:lang="en">Musch D.C., Gillespie B.W., Lichter P.R. et al. Visual field progres¬sion in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology. 2009; 116(2):200-207.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000; 130(4):429-440.</mixed-citation><mixed-citation xml:lang="en">AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000; 130(4):429-440.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Gedde S.J., Schiffman J.C., Feuer W.J. et al. Tube versus Trabeculec¬tomy Study Group Treatment outcomes in the Tube Versus Trabecu¬lectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012; 153(5):789-803.</mixed-citation><mixed-citation xml:lang="en">Gedde S.J., Schiffman J.C., Feuer W.J. et al. Tube versus Trabeculec¬tomy Study Group Treatment outcomes in the Tube Versus Trabecu¬lectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012; 153(5):789-803.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Tran D.H., Souza C., Ang M.J. et al. Comparison of long-term surgical success of Ahmed Valve implant versus trabeculectomy in open-angle glaucoma. Br J Ophthalmol. 2009; 93(11):1504-1509.</mixed-citation><mixed-citation xml:lang="en">Tran D.H., Souza C., Ang M.J. et al. Comparison of long-term surgical success of Ahmed Valve implant versus trabeculectomy in open-angle glaucoma. Br J Ophthalmol. 2009; 93(11):1504-1509.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kass M.A., Heuer D.K., Higginbotham E.J. et al. The Ocular Hyper¬tension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120(6):701-713.</mixed-citation><mixed-citation xml:lang="en">Kass M.A., Heuer D.K., Higginbotham E.J. et al. The Ocular Hyper¬tension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120(6):701-713.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеев В.Н., Мартынова Е.Б., Левко М.А. Подходы к определе¬нию целевого давления и его достижение комбинированным пре¬паратом фотил. РМЖ Клиническая офтальмология. 2006; 1:28-31.</mixed-citation><mixed-citation xml:lang="en">Alexeev V.N., Martynova E.B., Levko M.A. Approaches to determina¬tion of target IOP-level and its achievement by the combined prepara¬tion fotil. RMJ Clinical Ophthalmology. 2006; 1:28-31 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Asia-Pacific Glaucoma Guidelines. Kugler Publication; 2016:145.</mixed-citation><mixed-citation xml:lang="en">Asia-Pacific Glaucoma Guidelines. Kugler Publication; 2016:145.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Laplace O., Bron A., Nordmann J.P. Management of ocular hyper¬tension and chronic open-angle glaucoma by French ophthalmolo¬gists: the role of target intraocular pressure. J Fr Ophtalmol. 2006; 29(4):353-358.</mixed-citation><mixed-citation xml:lang="en">Laplace O., Bron A., Nordmann J.P. Management of ocular hyper¬tension and chronic open-angle glaucoma by French ophthalmolo¬gists: the role of target intraocular pressure. J Fr Ophtalmol. 2006; 29(4):353-358.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Vorwerk C., Thelen U., Buchholz P., Kimmich F. Treatment of glau¬coma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practice. Curr Med Res Opin. 2008; 24(5):1295-1301.</mixed-citation><mixed-citation xml:lang="en">Vorwerk C., Thelen U., Buchholz P., Kimmich F. Treatment of glau¬coma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practice. Curr Med Res Opin. 2008; 24(5):1295-1301.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Флетчер Р., Флечер С., Вагнер Э. Клиническая эпидемиология. Москва: Медиасфера; 1998:346.</mixed-citation><mixed-citation xml:lang="en">Fletcher R., Flecher S., Vagner E. Klinicheskaya epidemiologiya [Clini¬cal Epidemiology]. Moscow, Mediasphera Publ.; 1998:346. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Собянин Н.А., Максимов А.Г., Гаврилова Т.В. Методика оценки длительности болезненности на примере заболеваний глаукомой. Военно-медицинский журнал. 2007; 328(2):62-63.</mixed-citation><mixed-citation xml:lang="en">Sobianin N.A., Maximov A.G., Gavrilova T.V. The methodology of assessing morbidity duration on the example of glaucoma. Voenno- Meditsinsky Zhurnal. 2007; 328(2):62-63. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Авдеев Р.В., Александров А.С., Басинский А.С. и др. Многоцентро¬вое исследование по определению структурно-функционального статуса зрительного анализатора при одновременном наличии в глазу глаукомы и возрастной макулярной дегенерации с выявле¬нием их корреляционных связей и степени взаимного влияния. Офтальмология Восточная Европа. 2013; 4:15-25.</mixed-citation><mixed-citation xml:lang="en">Avdeev R.V., Aleksandrov A.S., Basinskii A.S. et al. Multicentre study of morphofunctional status of visual analyzer in simultane¬ous presence in eye glaucoma and age-related macular degeneration with determination of correlations and connections. Ophthalmology Eastern Europe. 2013; 4:15-25. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Авдеев Р.В., Александров А.С., Бакунина Н.А. и др. Прогнозирова¬ние продолжительности сроков заболевания и возраста пациен¬тов с разными стадиями первичной открытоугольной глаукомы. Национальный журнал глаукома. 2014; 13(2):60-69.</mixed-citation><mixed-citation xml:lang="en">Avdeev R.V., Alexandrov A.S., Bakynina N.A. et al. Prediction of the disease duration and the age of patients with different stages of pri¬mary open-angle glaucoma. Natsional’nyi zhurnal glaukoma. 2014; 13(2):60-69. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Куроедов А.В., Абышева Л.Д., Авдеев Р.В. и др. Результаты изуче¬ния соотношения эффективности и стоимости затрат при при¬менении местной гипотензивной терапии у пациентов с продви¬нутыми стадиями первичной открытоугольной глаукомы (мно¬гоцентровое исследование). Российский офтальмологический журнал. 2015; 8(3):10-22.</mixed-citation><mixed-citation xml:lang="en">Kuroedov A.V., Abysheva L.D., Avdeev R.V. et al. The cost-effective¬ness ratio study during local hypotensive therapy in patients with advanced primary open angle glaucoma (multicenter study). Russian Ophthalmological Journal. 2015; 8(3):10-22. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Абышева Л.Д., Авдеев Р.В., Александров А.С. и др. Много¬центровое исследование по изучению показателей офталь¬мотонуса у пациентов с продвинутыми стадиями первичной открытоугольной глаукомы на фоне проводимого лечения. Офтальмологические ведомости. 2015; 8(1):43-60.</mixed-citation><mixed-citation xml:lang="en">Abysheva L.D., Avdeev R.V., Alexandrov A.S. et al. Multicenter study of IOP level in patients with moderate and advanced primary open- angle glaucoma on treatment. Ophthalmologic vedomosti. 2015; 8(1):43-60. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Абышева Л.Д., Авдеев Р.В., Александров А.С. и др. Оптималь¬ные характеристики верхней границы офтальмотонуса у паци¬ентов с развитой стадией первичной открытоугольной глауко¬мы с точки зрения доказательной медицины. РМЖ Клиническая офтальмология. 2015; 16(3):111-123.</mixed-citation><mixed-citation xml:lang="en">Abysheva L.D., Avdeev R.V., Aleksandrov A.S. et al. Optimum upper level of IOP in patients with advanced primary open angle glaucoma in terms of evidence-based medicine. RMJ Clinical Ophthalmology. 2015; 8(3):111-123. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Абышева Л.Д., Александров А.С., Арапиев М.У. и др. Оптимиза¬ция лечебно-диагностического процесса у пациентов с первичной открытоугольной глаукомой. Национальный журнал глаукома. 2016; 15(2):19-35.</mixed-citation><mixed-citation xml:lang="en">Abysheva L.D., Aleksandrov A.S., Arapiev M.U. Optimization of diag¬nosis and treatment options in primary open-angle glaucoma patients. Natsional’nyi zhurnal glaukoma. 2016; 15(2):19-35. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Абышева Л.Д., Авдеев Р.В., Александров А.С. и др. Влияние местной гипотензивной терапии глаукомы на развитие и про¬грессирование синдрома «сухого глаза». РМЖ Клиническая офтальмология. 2017; 18(2):74-82</mixed-citation><mixed-citation xml:lang="en">Abysheva L.D., Avdeev R.V., Alexandrov A.S. et al. Influence of topical glaucoma hypotensive therapy on the development and progression of dry eye syndrome. RMJ Clinical Ophthalmology. 2017; 18(2):74-82. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Авдеев Р.В., Александров А.С., Арапиев М.У. и др. Подозрение и начальная стадия глаукомы: дифференциально-диагностиче¬ские критерии. Российский офтальмологический журнал. 2017; 10(4):5-15.</mixed-citation><mixed-citation xml:lang="en">Avdeev R.V., Alexandrov A.S., Arapiev M.U. et al. Suspected glauco¬ma and early stage glaucoma: differential diagnostic criteria. Russian Ophthalmological Journal. 2017; 10(4):5-15. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Авдеев Р.В., Александров А.С., Бакунина Н.А. и др. Сопоставление режимов лечения больных с первичной открытоугольной глауко¬мой с характеристиками прогрессирования заболевания. Часть 1. Состояние показателей офтальмотонуса. Национальный журнал глаукома. 2018; 17(1):14-28.</mixed-citation><mixed-citation xml:lang="en">Avdeev R.V., Alexandrov A.S., Bakunina N.A. et al. Comparison of treatment regimens for patients with primary open-angle glaucoma with signs of disease progression. Part 1. IOP levels. Natsional’nyi zhurnal glaukoma. 2018; 17(1):14-28. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Alm A., Grunden J.W., Kwok K.K. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. JGlaucoma. 2011; 20(4):215-222.</mixed-citation><mixed-citation xml:lang="en">Alm A., Grunden J.W., Kwok K.K. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. J Glaucoma. 2011; 20(4):215-222.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Егоров Е.А., Куроедов А.В. Отдельные клинико-эпидемиологиче¬ские характеристики глаукомы в странах СНГ и Грузии. Результа¬ты многоцентрового открытого ретроспективного исследования (часть 1). РМЖ Клиническая офтальмология. 2011; 3:97-100.</mixed-citation><mixed-citation xml:lang="en">Egorov E.A., Kuroyedov A.V. Clinical and epidemiological characte¬ristics of glaucoma in CIS and Georgia. Results of multicenter opened retrospective trial (part 1). RMJ Clinical Ophthalmology. 2011; 3:97¬</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Нероев В.В., Киселева О.А., Бессмертный А.М. Основные результа¬ты мультицентрового исследования эпидемиологических особен¬ностей первичной открытоугольной глаукомы в Российской Феде¬рации. Российский офтальмологический журнал. 2013; 6(3):4-7.</mixed-citation><mixed-citation xml:lang="en">(In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Pamberg P. How clinical trial results are changing our thinking about target pressures. Curr Opin Ophthalmol. 2002; 13(2):85-88.</mixed-citation><mixed-citation xml:lang="en">Neroev V.V., Kiseleva O.A., Bessmertny A.M. The main results of a multicenter study of epidemiological features of primary open- angle glaucoma in the Russian Federation. Russian Ophthalmological Journal. 2013; 6(3):4-7. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Шевелева Л.Н., Леонова А.Г. Сроки развития глаукоматозной экс¬кавации диска зрительного нерва и связь их с различными факто¬рами. Труды Казахского НИИ ГБ. 1968; 1:195-204.</mixed-citation><mixed-citation xml:lang="en">Pamberg P. How clinical trial results are changing our thinking about target pressures. Curr Opin Ophthalmol. 2002; 13(2):85-88.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">van der Valk R., Webers S.A.B., Schouten J.S.A.G et al. Intraocu¬lar pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005; 112(7):1177-1185.</mixed-citation><mixed-citation xml:lang="en">Sheveleva L.N., Leonova A.G. Terms of development of glaucoma¬tous excavation of the optic nerve disc and their connection with vari¬ous factors. Scientific works of The Kazakh Research Institute of Eye Diseases. 1968; 1:195-204. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Рациональная фармакотерапия в офтальмологии: Руководство для практикующих врачей / под общ. ред. Е.А. Егорова. Москва: Литтерра; 2004:954.</mixed-citation><mixed-citation xml:lang="en">van der Valk R., Webers S.A.B., Schouten J.S.A.G et al. Intraocu¬lar pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005; 112(7):1177-1185.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Куроедов А.В. Агрессия против прогрессии: как мы понимаем эффективность комбинированных антиглаукомных препаратов (обзор литературы). РМЖ Клиническая офтальмология. 2008; 4:143-146.</mixed-citation><mixed-citation xml:lang="en">Ratsional’naya farmakoterapiya v oftal’mologii: Rukovodstvo dlya praktikuyuschikh vrachey [Rational pharmacotherapy in ophthalmol¬ogy: A Guide for Practitioners]. Ed. by E.A. Egorov. Moscow: Litterra; 2004:954 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Weinreb R.N., Ong T., Scassellatti Storzolini B. A randomised, con¬trolled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open-angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015; 99(6):738-745.</mixed-citation><mixed-citation xml:lang="en">Kuroyedov A.V. Agression against progression: how we understand efficiency of combined antiglaucoma drugs (literary review). RMJ Clinical Ophthalmology. 2008; 4:143-146 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Andres-Guerrero V., Garcia-Feijoo J., Konstas A.G. Targeting Schlemm’s Canal in the Medical Therapy of Glaucoma: Current and Future Con¬siderations. Adv Ther. 2017; 34(5):1049-1069.</mixed-citation><mixed-citation xml:lang="en">Weinreb R.N., Ong T., Scassellatti Storzolini B. A randomised, con¬trolled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open-angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015; 99(6):738-745.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Егоров Е.А., Алексеев В.Н., Мартынова Е.Б. и др. Патогенетиче¬ские аспекты лечения первичной открытоугольной глаукомы. Москва; 2001:118.</mixed-citation><mixed-citation xml:lang="en">Andres-Guerrero V., Garcia-Feijoo J., Konstas A.G. Targeting Schlemm’s Canal in the Medical Therapy of Glaucoma: Current and Future Con¬siderations. Adv Ther. 2017; 34(5):1049-1069.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Bucci M.G. Intraocular pressure-lowering effects of latanoprost mono¬therapy versus latanoprost or pilocarpine in combination with timo¬lol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma. 1999; 8(1):24-30.</mixed-citation><mixed-citation xml:lang="en">Egorov E.A., Alekseev V.N., Martynova E.B. et al. Pathogenic aspects of primary open-angle glaucoma treatment. Moscow; 2001:118. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Аветисов С.Э., Мамиконян В.Р., Казарян Э.Э. и др. Результаты клинической оценки нового скринингового метода определе¬ния индивидуальной нормы внутриглазного давления. Вестник офтальмологии. 2010; 126(2):5-7</mixed-citation><mixed-citation xml:lang="en">Bucci M.G. Intraocular pressure-lowering effects of latanoprost mono¬therapy versus latanoprost or pilocarpine in combination with timo¬lol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma. 1999; 8(1):24-30.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Neelakantan A., Vaishnav H.D., Iyer S.A., Sherwood M.B. Is additional of a third or fourth antiglaucoma medication effective? J Glaucoma. 2004; 13(2):130-136.</mixed-citation><mixed-citation xml:lang="en">Avetisov S.E., Mamikonyan V.R., Kazaryan E.E. et al. Results of clini¬cal evaluation of new screening method of individual normal level of intraocular pressure evaluation. Vestn Oftalmol. 2010; 126(2):5-7 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma S., Trikha S., Perera S.A., Aung T. Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for prima¬ry open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2015; 24(9):2201-2207.</mixed-citation><mixed-citation xml:lang="en">Neelakantan A., Vaishnav H.D., Iyer S.A., Sherwood M.B. Is additional of a third or fourth antiglaucoma medication effective? J Glaucoma. 2004; 13(2):130-136.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Hollo G., Vuorinen J., Tuominen J. et al. Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014; 31(9):932-944.</mixed-citation><mixed-citation xml:lang="en">Sharma S., Trikha S., Perera S.A., Aung T. Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for prima¬ry open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2015; 24(9):2201-2207.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis R.A., Levy B., Ramirez N. et al. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2016; 100(3):339-344.</mixed-citation><mixed-citation xml:lang="en">Hollo G., Vuorinen J., Tuominen J. et al. Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014; 31(9):932-944.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Lopez A., Paczka J.A., Jimenez-Roman J., Hartleben C. Effica¬cy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study. BMC. Ophthalmology. 2014; 19:161-172.</mixed-citation><mixed-citation xml:lang="en">Lewis R.A., Levy B., Ramirez N. et al. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2016; 100(3):339-344.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Hartleben C., Parra J.C., Batoosingh A. et al. A Masked, randomized, phase 3 comparison of triple fixed-combination bimatoprost/brimoni- dine/timolol versus fixed-combination brimonidine/timolol for low¬ering intraocular pressure. Hindawi J Ophthalmol. 2017; 9:1-9.</mixed-citation><mixed-citation xml:lang="en">Garcia-Lopez A., Paczka J.A., Jimenez-Roman J., Hartleben C. Effica¬cy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study. BMC. Ophthalmology. 2014; 19:161-172.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Schulzer M. Intraocular pressure reduction in normal-tension glaucoma patients. The Normal Tension Glaucoma Study Group. Ophthalmology. 1992; 99(9):1468-1470.</mixed-citation><mixed-citation xml:lang="en">Hartleben C., Parra J.C., Batoosingh A. et al. A Masked, randomized, phase 3 comparison of triple fixed-combination bimatoprost/brimoni- dine/timolol versus fixed-combination brimonidine/timolol for low¬ering intraocular pressure. Hindawi J Ophthalmol. 2017; 9:1-9.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Krupin T., Liebmann J.M, Greenfield D.S. et al. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. Am J Ophthalmol. 2011; 151(4): 671-681.</mixed-citation><mixed-citation xml:lang="en">Schulzer M. Intraocular pressure reduction in normal-tension glaucoma patients. The Normal Tension Glaucoma Study Group. Ophthalmology. 1992; 99(9):1468-1470.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng J.W., Cai J.P., Wei R.L. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009; 116(7):1243- 1249.</mixed-citation><mixed-citation xml:lang="en">Krupin T., Liebmann J.M, Greenfield D.S. et al. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. Am J Ophthalmol. 2011; 151(4): 671-681.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Kim T.W., Kim M., Lee E.J. et al. Intraocular pressure-lowering effica¬cy of dorzolamide/timolol fixed combination in normal-tension glau¬coma. J Glaucoma. 2014; 23(5):329-332.</mixed-citation><mixed-citation xml:lang="en">Cheng J.W., Cai J.P., Wei R.L. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009; 116(7):1243- 1249.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Igarashi R., Togano T., Sakaue Y. et al. Effect on intraocular pressure of switching from latanoprost and travoprost monotherapy to timo¬lol fixed combinations in patients with normal-tension glaucoma. J Ophthalmol. 2014; 2014:720385.</mixed-citation><mixed-citation xml:lang="en">Kim T.W., Kim M., Lee E.J. et al. Intraocular pressure-lowering effica¬cy of dorzolamide/timolol fixed combination in normal-tension glau¬coma. J Glaucoma. 2014; 23(5):329-332.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Kim J.M., Kim T.W., Kim C.Y. et al. Comparison of the intraocu¬lar pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5% timolol in normal-tension glaucoma patients. Jpn J Ophthalmol. 2016; 60(1):20-26.</mixed-citation><mixed-citation xml:lang="en">Igarashi R., Togano T., Sakaue Y. et al. Effect on intraocular pressure of switching from latanoprost and travoprost monotherapy to timo¬lol fixed combinations in patients with normal-tension glaucoma. J Ophthalmol. 2014; 2014:720385.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Kim M., Kim D.M., Park K.H. Intraocular pressure reduction with topical medications and progression of normal-tension glaucoma: a 12-year mean follow-up study. Acta Ophthalmol. 2013; 91(4):e270-275.</mixed-citation><mixed-citation xml:lang="en">Kim J.M., Kim T.W., Kim C.Y. et al. Comparison of the intraocu¬lar pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5% timolol in normal-tension glaucoma patients. Jpn J Ophthalmol. 2016; 60(1):20-26.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Komori S., Ishida K., Yamamoto T. Results of long-term monitoring of normal-tension glaucoma patients receiving medical therapy: results of an 18-year follow-up. Graefes Arch Clin Exp Ophthalmol. 2014; 252(12):1963-1970.</mixed-citation><mixed-citation xml:lang="en">Kim M., Kim D.M., Park K.H. Intraocular pressure reduction with topical medications and progression of normal-tension glaucoma: a 12-year mean follow-up study. Acta Ophthalmol. 2013; 91(4):e270-275.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Konstas A.G., Hollo G., Astakhov Y.S. et al. Factors associated with long-term progression or stability in exfoliation glaucoma. Arch. Ophthalmol. 2004; 122(1):29-33.</mixed-citation><mixed-citation xml:lang="en">Komori S., Ishida K., Yamamoto T. Results of long-term monitoring of normal-tension glaucoma patients receiving medical therapy: results of an 18-year follow-up. Graefes Arch Clin Exp Ophthalmol. 2014; 252(12):1963-1970.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Katz L., Spaeth G., Cantor L. et al. Reversible optic disc cupping and visual field improvement in adults with glaucoma. Am J Ophthalmol. 1989; 107(5):485-492.</mixed-citation><mixed-citation xml:lang="en">Konstas A.G., Hollo G., Astakhov Y.S. et al. Factors associated with long-term progression or stability in exfoliation glaucoma. Arch. Ophthalmol. 2004; 122(1):29-33.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Blika S., Saunte E. Timolol maleate in the treatment of glauco¬ma simplex and glaucoma capsulare. A three-year follow up study. Acta Ophthalmol. 1982; 60(6):967-976.</mixed-citation><mixed-citation xml:lang="en">Katz L., Spaeth G., Cantor L. et al. Reversible optic disc cupping and visual field improvement in adults with glaucoma. Am J Ophthalmol. 1989; 107(5):485-492.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Konstas A.G., Mantziris D.A., Cate E.A. et al. Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997; 115(8):975-979.</mixed-citation><mixed-citation xml:lang="en">Blika S., Saunte E. Timolol maleate in the treatment of glauco¬ma simplex and glaucoma capsulare. A three-year follow up study. Acta Ophthalmol. 1982; 60(6):967-976.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Konstas A.G., Kozobolis V.P., Tsironi S. et al. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dor- zolamide/timolol fixed combination after 2 and 6 months of treat¬ment. Ophthalmology. 2008; 115:99-103.</mixed-citation><mixed-citation xml:lang="en">Konstas A.G., Mantziris D.A., Cate E.A. et al. Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997; 115(8):975-979.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Konstas A.G., Koliakos G.G., Karabatsas C.H. et al. Latanoprost the¬rapy reduces the levels of TGF beta 1 and gelatinases in the aqueous humour of patients with exfoliative glaucoma. Exp. Eye Res. 2006; 82(2):319-322.</mixed-citation><mixed-citation xml:lang="en">Konstas A.G., Kozobolis V.P., Tsironi S. et al. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dor- zolamide/timolol fixed combination after 2 and 6 months of treat¬ment. Ophthalmology. 2008; 115:99-103.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Konstas A.G., Maltezos A., Bufidis T. et al. Twenty-four hour con¬trol of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma. Eye (Lond). 2000; 14(Pt.1):73-77.</mixed-citation><mixed-citation xml:lang="en">Konstas A.G., Koliakos G.G., Karabatsas C.H. et al. Latanoprost the¬rapy reduces the levels of TGF beta 1 and gelatinases in the aqueous humour of patients with exfoliative glaucoma. Exp. Eye Res. 2006; 82(2):319-322.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Parmaksiz S., Yuksel N., Karabas V.L. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol. 2006; 6(1):73-80.</mixed-citation><mixed-citation xml:lang="en">Konstas A.G., Maltezos A., Bufidis T. et al. Twenty-four hour con¬trol of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma. Eye (Lond). 2000; 14(Pt.1):73-77.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">pressure control with evening-dosed travoprost/timolol, com¬pared with latanoprost/timolol, fixed combinations in exfoliative glaucoma. Eye (London). 2010; 24(10):1606-1613.</mixed-citation><mixed-citation xml:lang="en">Parmaksiz S., Yuksel N., Karabas V.L. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol. 2006; 6(1):73-80.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Konstas A.G., Hollo G., Mikropoulos D. et al. Twenty-four hour intra¬ocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfolia¬tive glaucoma. Br JOphthalmol. 2010; 94(2):209-213.</mixed-citation><mixed-citation xml:lang="en">Konstas A.G., Mikropoulos D.G., Embeslidis T.A. et al. 24-hour intra¬ocular pressure control with evening-dosed travoprost/timolol, com¬pared with latanoprost/timolol, fixed combinations in exfoliative glaucoma. Eye (London). 2010; 24(10):1606-1613.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Hollo G., Ropo A. Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoex¬foliative glaucoma. Curr Med Res Opin. 2015; 31(1):13-16.</mixed-citation><mixed-citation xml:lang="en">Konstas A.G., Hollo G., Mikropoulos D. et al. Twenty-four hour intra¬ocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfolia¬tive glaucoma. Br J Ophthalmol. 2010; 94(2):209-213.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Тачиева Е.С. Влияние пилокарпина на офтальмотонус здоровых, глаукомных глаз и глаукомных глаз с псевдоэксфолиативным син-дромом. РМЖ Клиническая офтальмология. 2004; 1:15-16.</mixed-citation><mixed-citation xml:lang="en">Hollo G., Ropo A. Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoex¬foliative glaucoma. Curr Med Res Opin. 2015; 31(1):13-16.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Angelilli A., Ritch R., Krupin T. et al. The International Collabora¬tive Exfoliation Syndrome Treatment (ICEST) Study: Results. Invest Ophthalmol Vis Sci. 2009; 50(13):2474.</mixed-citation><mixed-citation xml:lang="en">Tachieva E.S. The influens of pilocarpini on ophthalmotonus of healthy, glaucoma eyes and glaucoma eyes with XFS. RMJ Clinical Ophthalmology. 2004; 1:15-16 (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Mastropasqua L., Carpineto P., Ciancaglini M., Gallenga P.E. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology. 1999; 106:550-555.</mixed-citation><mixed-citation xml:lang="en">Angelilli A., Ritch R., Krupin T. et al. The International Collabora¬tive Exfoliation Syndrome Treatment (ICEST) Study: Results. Invest Ophthalmol Vis Sci. 2009; 50(13):2474.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Grierson I., Jonsson M., Cracknell K. Latanoprost and pigmentation. Jpn J Ophthalmol. 2004; 48:602-612.</mixed-citation><mixed-citation xml:lang="en">Mastropasqua L., Carpineto P., Ciancaglini M., Gallenga P.E. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology. 1999; 106:550-555.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Куроедов А.В., Брежнев А.Ю. Продолжительность гипотензив¬ного действия антиглаукомных препаратов. РМЖ Клиническая офтальмология. 2016; 17(4):214-219.</mixed-citation><mixed-citation xml:lang="en">Grierson I., Jonsson M., Cracknell K. Latanoprost and pigmentation. Jpn J Ophthalmol. 2004; 48:602-612.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Covert D., Robin A.L. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin. 2006; 22(5):971-976.</mixed-citation><mixed-citation xml:lang="en">Kuroyedov A.V., Brezhnev A.Yu. The duration of the hypotensive action of anti-glaucoma medicines. RMJ Clinical Ophthalmology. 2016; 17(4):214-219. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Noecker R.J., Dirks M.S., Choplin N.T. et al. Comparison of latano- prost, bimatoprost, and travoprost in patients with elevated intraocu¬lar pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2004; 137(1):210-211.</mixed-citation><mixed-citation xml:lang="en">Covert D., Robin A.L. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin. 2006; 22(5):971-976.</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Куроедов А.В., Брежнев А.Ю., Александров А.С. Как понизить уровень внутриглазного давления на 30% у пациентов с глау¬комой (обзор литературы). Военно-медицинский журнал. 2009; 330(6):40-46.</mixed-citation><mixed-citation xml:lang="en">Noecker R.J., Dirks M.S., Choplin N.T. et al. Comparison of latano- prost, bimatoprost, and travoprost in patients with elevated intraocu¬lar pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2004; 137(1):210-211.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Blica S., Saunte E. Timolol maleate in the treatment of glaucoma simplex and glaucoma capsulare. A three-year follow up study. Acta Ophthalmol. (Copenh). 1982; 60(6):967-976.</mixed-citation><mixed-citation xml:lang="en">Kuroyedov A.V., Brezhnev A.Yu., Aleksandrov A.S. Principles of reduc¬tion of ophthalmotonous pressure on 30% by the patients with glau¬coma (Review of literature). Voenno-meditsinskiy zhurnal. 2009; 330(6):40-46. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Kobelt, G. Comparative data for all countries. In: Jonsson B., Kriegl- stein G., eds. Primary open-angle glaucoma. Differences in interna¬tional treatment patterns and costs. Oxford, England: ISIS Medical Media; 1998:116-126.</mixed-citation><mixed-citation xml:lang="en">Blica S., Saunte E. Timolol maleate in the treatment of glaucoma simplex and glaucoma capsulare. A three-year follow up study. Acta Ophthalmol. (Copenh). 1982; 60(6):967-976.</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Куроедов А.В., Криницына Е.А., Сергеева В.М., Городничий В.В. Изменение структуры клинико-эпидемиологических показате¬лей первичной открытоугольной глаукомы за 10 лет у пациен¬тов, поступающих на оперативное лечение. РМЖ Клиническая офтальмология. 2017; 18(4):205-212.</mixed-citation><mixed-citation xml:lang="en">Kobelt, G. Comparative data for all countries. In: Jonsson B., Kriegl- stein G., eds. Primary open-angle glaucoma. Differences in interna¬tional treatment patterns and costs. Oxford, England: ISIS Medical Media; 1998:116-126.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Inoue K., Okayama R., Higa R. Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combina¬tion to a latanoprost 0.005% + timolol maleate 0.5% fixed combina¬tion. Clin Ophthalmol. 2012; 6:607-612.</mixed-citation><mixed-citation xml:lang="en">Kuroyedov A.V., Krinitsyna E.A., Sergeeva V.M., Gorodnichiy V.V. Changes in the structure of clinical and epidemiological characteris¬tics of primary open-angle glaucoma over 10 years in patients coming to surgical treatment. RMJ Clinical Ophthalmology. 2017; 18(4):205- 212. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Manni G., Denis P., Chew P. et al. The safety and efficacy of brinzo- lamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/ timolol 0.5% in patients with open-angle glaucoma or ocular hyper¬tension. J Glaucoma. 2009; 18(4):293-300.</mixed-citation><mixed-citation xml:lang="en">Inoue K., Okayama R., Higa R. Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combina¬tion to a latanoprost 0.005% + timolol maleate 0.5% fixed combina¬tion. Clin Ophthalmol. 2012; 6:607-612.</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Schwenn O., Heckmann B., Guzy C., Miller P.J. Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study. BMC. Ophthalmology. 2010; 10:21-29.</mixed-citation><mixed-citation xml:lang="en">Manni G., Denis P., Chew P. et al. The safety and efficacy of brinzo- lamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/ timolol 0.5% in patients with open-angle glaucoma or ocular hyper¬tension. J Glaucoma. 2009; 18(4):293-300.</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Апостолова А.С. Наш опыт применения фиксированной ком¬бинации травопроста 0,004% с тимолола малеатом 0,5% (Дуо- Трав, Akon) в лечении псевдоэксфолиативной глаукомы. РМЖ Клиническая офтальмология. 2014; 14(3):135-139</mixed-citation><mixed-citation xml:lang="en">Schwenn O., Heckmann B., Guzy C., Miller P.J. Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study. BMC. Ophthalmology. 2010; 10:21-29.</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Inoue K., Okayama R., Higa R., Tomita G. Efficacy and safety of switching to latanoprost 0.005%-timolol maleate 0.5% fixed-com¬bination eyedrops from an unfixed combination for 36 months. Clin Ophthalmol. 2014; 8:1275-1279.</mixed-citation><mixed-citation xml:lang="en">Apostolova A.S. Our experience of prescription of a fixed combi¬nation of travoprost 0.004% and timolol maleate 0.5% (DuoTrav, Alcon) in the treatment of pseudoexfoliative glaucoma. RMJ Clinical Ophthalmology. 2014; 14(3):135-139. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Pajic B., Pajic-Eggspuehler B., Hafliger I.O. Comparison of the effects of dorzolamide/timolol and latanoprost/timolol fixed combinations upon intraocular pressure and progression of visual field damage in primary open-angle glaucoma. Curr Med Res Opin. 2010; 26(9):2213- 2219.</mixed-citation><mixed-citation xml:lang="en">Inoue K., Okayama R., Higa R., Tomita G. Efficacy and safety of switching to latanoprost 0.005%-timolol maleate 0.5% fixed-com¬bination eyedrops from an unfixed combination for 36 months. Clin Ophthalmol. 2014; 8:1275-1279.</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Cillino S., Di Pace F., Casuccio A. et al. Deep sclerectomy versus tra-beculectomy with low-dosage mitomycin C: four-year follow-up. Ophthalmologica. 2008; 222(2):81-87.</mixed-citation><mixed-citation xml:lang="en">Pajic B., Pajic-Eggspuehler B., Hafliger I.O. Comparison of the effects of dorzolamide/timolol and latanoprost/timolol fixed combinations upon intraocular pressure and progression of visual field damage in primary open-angle glaucoma. Curr Med Res Opin. 2010; 26(9):2213- 2219.</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Cillino S., Di Pace F., Casuccio A. et al. Deep sclerectomy versus tra-beculectomy with low-dosage mitomycin C: four-year follow-up. Ophthalmologica. 2008; 222(2):81-87.</mixed-citation><mixed-citation xml:lang="en">Cillino S., Di Pace F., Casuccio A. et al. Deep sclerectomy versus tra-beculectomy with low-dosage mitomycin C: four-year follow-up. Ophthalmologica. 2008; 222(2):81-87.</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Ehrnrooth P., Lehto I., Puska P., Laatikainen L. Long-term outcome of trabeculectomy in terms of intraocular pressure. Acta Ophthalmol. (Scand). 2002; 80(3):267-271.</mixed-citation><mixed-citation xml:lang="en">Ehrnrooth P., Lehto I., Puska P., Laatikainen L. Long-term outcome of trabeculectomy in terms of intraocular pressure. Acta Ophthalmol. (Scand). 2002; 80(3):267-271.</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Gedde S.J., Schiffman J.C., Feuer W.J. et al. Three-year follow-up of the tube versus trabeculectomy study. Am J Ophthalmol. 2009; 148(5):670-684.</mixed-citation><mixed-citation xml:lang="en">Gedde S.J., Schiffman J.C., Feuer W.J. et al. Three-year follow-up of the tube versus trabeculectomy study. Am J Ophthalmol. 2009; 148(5):670-684.</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Shah P., Agrawal P., Khaw P.T. et al. ReGAE 7: long-term outcomes of augmented trabeculectomy with mitomycin C in African Caribbe¬an patients. Clin Exp Ophthalmol. 2012; 40(4):e176-182.</mixed-citation><mixed-citation xml:lang="en">Shah P., Agrawal P., Khaw P.T. et al. ReGAE 7: long-term outcomes of augmented trabeculectomy with mitomycin C in African Caribbe¬an patients. Clin Exp Ophthalmol. 2012; 40(4):e176-182.</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Jayaram H., Strouthidis N.G., Kamal D.S. Trabeculectomy for nor¬mal tension glaucoma: outcomes using the Moorfields Safer Surgery technique. Br J Ophtalmol. 2016; 100(3):332-338.</mixed-citation><mixed-citation xml:lang="en">Jayaram H., Strouthidis N.G., Kamal D.S. Trabeculectomy for nor¬mal tension glaucoma: outcomes using the Moorfields Safer Surgery technique. Br J Ophtalmol. 2016; 100(3):332-338.</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Five-year follow-up of the Fluorouracil Filtering Surgery Study. The Fluorouracil Filtering Surgery Study Group. Am J Ophthalmol. 1996; 121(4):349-366.</mixed-citation><mixed-citation xml:lang="en">Five-year follow-up of the Fluorouracil Filtering Surgery Study. The Fluorouracil Filtering Surgery Study Group. Am J Ophthalmol. 1996; 121(4):349-366.</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Козлов В.И., Козлова Е.Е., Соколовская Т.В., Сидорова А.В. При¬чины повышения внутриглазного давления в ближайшие и отда¬ленные сроки после непроникающей глубокой склерэктомии в хирургии открытоугольной глаукомы. Перспективные направле¬ние в хирургическом лечении глаукомы. Сб. научн. ст. Москва; 1997:50-53.</mixed-citation><mixed-citation xml:lang="en">Kozlov V.I., Kozlova E.E., Sokolovskaya T.V., Sidorova A.V. Causes of elevated intraocular pressure in the early and late periods after non-penetrating deep sclerectomy in open-angle glaucoma surgery. A promising direction in the surgical treatment of glaucoma. Collec¬tion of scientific works. Moscow; 1997:50-53. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Russo V., Scott I.U., Stella A. et al. Nonpenetrating deep sclerectomy with reticulated hyaluronic acid implant versus punch trabeculecto¬my: a prospective clinical trial. Eur J Ophthalmol. 2008; 18(5):751- 757.</mixed-citation><mixed-citation xml:lang="en">Russo V., Scott I.U., Stella A. et al. Nonpenetrating deep sclerectomy with reticulated hyaluronic acid implant versus punch trabeculecto¬my: a prospective clinical trial. Eur J Ophthalmol. 2008; 18(5):751- 757.</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng J.W. Systematic overview of the efficacy of non-penetrating surgery in the treatment of open angle glaucoma. Med Sci Monit. 2011; 17(7):110-115.</mixed-citation><mixed-citation xml:lang="en">Cheng J.W. Systematic overview of the efficacy of non-penetrating surgery in the treatment of open angle glaucoma. Med Sci Monit. 2011; 17(7):110-115.</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Lin L., Zhao Y.J., Chew P.T. et al. Comparative efficacy and tolerabili¬ty of topical prostaglandin analogues for primary open-angle glauco¬ma and ocular hypertension. AnnPharmacother. 2014; 48(12):1585- 1593.</mixed-citation><mixed-citation xml:lang="en">Lin L., Zhao Y.J., Chew P.T. et al. Comparative efficacy and tolerabili¬ty of topical prostaglandin analogues for primary open-angle glauco¬ma and ocular hypertension. Ann Pharmacother. 2014; 48(12):1585- 1593.</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Xing Y., Jiang F.G., Li T. Fixed combination of latanoprost and timo¬lol vs the individual components for primary open angle glaucoma and ocular hypertension: a systematic review and meta-analysis. Int J Ophthalmol. 2014; 18;7(5):879-890.</mixed-citation><mixed-citation xml:lang="en">Xing Y., Jiang F.G., Li T. Fixed combination of latanoprost and timo¬lol vs the individual components for primary open angle glaucoma and ocular hypertension: a systematic review and meta-analysis. Int J Ophthalmol. 2014; 18;7(5):879-890.</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng J.W., Cheng S.W., Gao L.D. et al. Intraocular pressure¬lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012; 7(9):e45079.</mixed-citation><mixed-citation xml:lang="en">Cheng J.W., Cheng S.W., Gao L.D. et al. Intraocular pressure¬lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012; 7(9):e45079.</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Japan Glaucoma Society Guidelines for Glaucoma (2nd Edition). Japan; 2006:61.</mixed-citation><mixed-citation xml:lang="en">Japan Glaucoma Society Guidelines for Glaucoma (2nd Edition). Japan; 2006:61.</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Translation of the Finnish Current Care Guideline for Glaucoma. Finland; 2014:23.</mixed-citation><mixed-citation xml:lang="en">Translation of the Finnish Current Care Guideline for Glaucoma. Finland; 2014:23.</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">Guidelines for Medical Management of primary open-angle glauco¬ma. All India Ophthalmological Society; 2011:56.</mixed-citation><mixed-citation xml:lang="en">Guidelines for Medical Management of primary open-angle glauco¬ma. All India Ophthalmological Society; 2011:56.</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">ICO Guidelines for Glaucoma Eye Care. International Council of Ophthalmology; 2015:22.</mixed-citation><mixed-citation xml:lang="en">ICO Guidelines for Glaucoma Eye Care. International Council of Ophthalmology; 2015:22.</mixed-citation></citation-alternatives></ref><ref id="cit114"><label>114</label><citation-alternatives><mixed-citation xml:lang="ru">Родионова Т.Е., Кадырова Г.Р. О применении метода ступенчато¬го оценивания при построении описательных моделей. Инфор¬мационные технологии и нанотехнологии. 2017: 1376-1379.</mixed-citation><mixed-citation xml:lang="en">Rodionova T.E., Kadyrova G.R. About the application of the step¬wise estimation method in the construction of descriptive models. Information technologies and nanotechnologies. 2017: 1376-1379. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit115"><label>115</label><citation-alternatives><mixed-citation xml:lang="ru">National Institutes of Health. International consensus report on diag¬nosis and treatment of asthma. Bethesda, USA. 1992. Publication No. 92-3091:62.</mixed-citation><mixed-citation xml:lang="en">National Institutes of Health. International consensus report on diag¬nosis and treatment of asthma. Bethesda, USA. 1992. Publication No. 92-3091:62.</mixed-citation></citation-alternatives></ref><ref id="cit116"><label>116</label><citation-alternatives><mixed-citation xml:lang="ru">Chobanian A.V., Bakris G.L. et al. Seventh report of the Joint Nation¬al Committee of prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003; 42:1206-1252.</mixed-citation><mixed-citation xml:lang="en">Chobanian A.V., Bakris G.L. et al. Seventh report of the Joint Nation¬al Committee of prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003; 42:1206-1252.</mixed-citation></citation-alternatives></ref><ref id="cit117"><label>117</label><citation-alternatives><mixed-citation xml:lang="ru">Broadway D.C., Grierson I., O’Brien C., Hitchings R.A. Adverse effects of topical antiglaucoma medication. II. The outcome of filtra¬tion surgery. Arch Ophthalmol. 1994; 112(11):1446-1454.</mixed-citation><mixed-citation xml:lang="en">Broadway D.C., Grierson I., O’Brien C., Hitchings R.A. Adverse effects of topical antiglaucoma medication. II. The outcome of filtra¬tion surgery. Arch Ophthalmol. 1994; 112(11):1446-1454.</mixed-citation></citation-alternatives></ref><ref id="cit118"><label>118</label><citation-alternatives><mixed-citation xml:lang="ru">Еричев В.П., Амбарцумян К.Г., Федоров А.А. Клинико-морфоло¬гические доказательства влияния консервантов на поверхность глаза при первичной открытоугольной глаукоме. Национальный журнал глаукома. 2014; 13(4):13-22.</mixed-citation><mixed-citation xml:lang="en">Erichev V.P., Ambartsumyan K.H., Fedorov A.A. Clinical and mor¬phological evidence of the effect of preservatives on the eye surface in primary open-angle glaucoma. Natsional’nyi zhurnal glaukoma. 2014; 13(4):13-22. (In Russ.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
